Gilead Requests Approval of Descovy for PrEP

Descovy and Truvada were both highly effective and generally safe options for HIV prevention in a recent clinical trial.

Gilead Sciences has submitted a supplemental new drug application requesting Food and Drug Administration (FDA) approval of its Descovy combination pill for pre-exposure prophylaxis (PrEP), according to a company press release. Descovy contains tenofovir alafenamide (TAF)—an updated formulation of tenofovir that is easier on the kidneys and bones—and emtricitabine.

To read article CLICK HERE